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The genetic etiology and the contribution of rare genetic variation in multiple sclerosis (MS) has not yet 
been elucidated. Although familial forms of MS have been described, no convincing rare and penetrant 
variants have been reported to date. We aimed to characterize the contribution of rare genetic variation 
in familial and sporadic MS and have identified a family with two sibs affected by concomitant MS 
and malignant melanoma (MM). We performed whole exome sequencing in this primary family and 
38 multiplex MS families and 44 sporadic MS cases and performed transcriptional and immunologic 
assessment of the identified variants. We identified a potentially causative homozygous missense 
variant in NLRP1 gene (Gly587Ser) in the primary family. Further possibly pathogenic NLRP1 variants 
were identified in the expanded cohort of patients. Stimulation of peripheral blood mononuclear 
cells from MS patients with putatively pathogenic NLRP1 variants showed an increase in IL-1B 
gene expression and active cytokine IL-1β production, as well as global activation of NLRP1-driven 
immunologic pathways. We report a novel familial association of MS and MM, and propose a possible 
underlying genetic basis in NLRP1 gene. Furthermore, we provide initial evidence of the broader 
implications of NLRP1-related pathway dysfunction in MS.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which leads to wide-
spread focal lesions of primary demyelination with variable axonal, neuronal and astroglia injury. Despite exten-
sive research, key aspects of multiple sclerosis etiology and pathogenesis still remain unresolved. It is considered 
that multiple and complex interactions between environment and genetic background lead to the manifestation 
of the disease. Nevertheless, neither environmental triggers nor highly penetrant genetic predisposition genes 
have yet been discovered. Familial contribution to MS etiology is well recognized and many cases of families with 
apparent monogenic inheritance have been reported However, in contrast to several other complex neurologi-
cal disorders no highly penetrant genetic variants have been described in MS yet. Exome sequencing of several 
MS families with multiple affected members has identified genetic variants in two genes, CYP27B1 and TYK2 
with the modest effect on MS risk1, 2. In a recently published study, a pathogenic variant in NR1H3 gene (p.Arg-
415Gln), has been reported in two independent families with an autosomal dominant pattern of inheritance3. In 
the reported two NR1H3 families, segregation with the disease was not complete and the same variant was also 
present among presumably healthy controls of the general population, making this association uncertain, based 
on the available evidence.
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In our study, we used whole-exome sequencing to identify a putative genetic cause in the nuclear family, where 
MS cosegregated with malignant melanoma (MM). In the nuclear family, we used exome sequencing in combi-
nation with homozygosity mapping to uncover a possibe causative homozygous NLRP1 gene variant in affected 
cases. To date, the association with MS and MM has only been reported in epidemiological surveys as comor-
bidities4, but evidence of familial co-occurrence and shared etiological origin of these two diseases has not been 
reported. Interestingly, studies have reported genetic association of variation in NLRP1 gene and susceptibility 
to MM, and there are recent reports supporting the role of NLRP1 in driving tumorigenic processes in malignant 
melanoma5.
We followed the initial finding by exploring the association of NLRP1 and MS in a wider set of patients with 
familial and sporadic MS. Based on these findings, we provide initial evidence of the broader implications of 
NLRP1-related pathway dysfunction in familial and sporadic MS.
Results
Identification of the primary family with concurrent multiple sclerosis and malignant mela-
noma. We identified a family with two sibs concurrently affected by multiple sclerosis and malignant mela-
noma (MSMM, Fig. 1).
In the male proband (MSMM001) fatigue and weakness of the lower extremities started at age 37. However, 
multiple sclerosis was first suspected at the age of 41, after an MRI scan was performed in diagnostic evaluation 
of a traumatic vertebral fracture. The scan has shown signs of bilateral demyelinating lesions in periventricular 
white matter. At the age of 43, the patient was hospitalized because of diplopia and blurred vision dominating in 
the right eye. Mild ataxia and spastic paraparesis were also noted. Cerebrospinal fluid analysis showed intrath-
ecal IgG synthesis and presence of oligoclonal bands. At the age of 50, the patient presented with left axilla lym-
phadenopathy, which was treated surgically. Perioperative biopsy showed the presence of S-100 positive atypical 
melanocytes, suggestive of malignant melanoma, and accordingly oncologic treatment was initiated. At the age of 
57, the patient developed symptoms of vitiligo progressing for 5 months. This was concurrent with development 
of massiveright axilla lymphadenopathy. The histologic evaluation confirmed presence of malignant melanoma 
cells and oncologic treatment was repeated. The most recent neurological evaluation was performed at the age of 
62 demonstrating the progression of MS (EDSS 4.5).
Proband’s sister (MSMM002) presented at the age of 40 with initial symptoms of MS, which included vertigo 
and right-sided hand and leg weakness. After quick remission, symptoms of blurred vision in the left eye and 
hand paresthesia appeared at the age of 42. MRI scan showed an hyper-intense lesion of the pons and multiple 
periventricular white matter lesions. Cerebrospinal fluid analysis showed intrathecal IgG synthesis and the pres-
ence of oligoclonal bands. At the age of 55 she was examined for suspicious nevus of the skin in the left hypo-
chondriac region of abdomen. Biopsy of the nevus confirmed the presence of malignant melanoma. The patient 
deteriorated severely to the age of 59 and demonstrated severe spastic paraparesis, mixed ataxia, urinary incon-
tinence and cognitive impairment (EDSS 9.0). She died at the age of 63 due to metastatic malignant melanoma.
Figure 1. Family segregation patterns and mutations detected in the MSMM Family. The family includes two 
probands (male MSMM001 and female MSMM002), concurrently affected by multiple sclerosis and malignant 
melanoma. Both probands were homozygous for a rare Gly578Ser predicted pathogenic variant in the NLRP1 
gene.
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In both reported cases, diagnosis of MS was established in accordance with McDonald criteria6. Both patients 
were treated with pulses of high-dose methylprednisolone at the time and both responded favorably to this treat-
ment. No immunomodulating or other specific treatment was prescribed apart from symptomatic treatment of 
disease manifestations.
The striking co-occurrence of the two presenting diseases directed us towards a search for potential rare 
genetic variants related to the observed phenotype in the presenting family. The parents of the two patients were 
not diagnosed with either multiple sclerosis or malignant melanoma. The inheritance pattern observed in the 
family suggested an autosomal recessive mode of inheritance.
Exome sequencing in the MSMM family. We performed whole exome sequencing in the two sibs con-
currently affected by MS and MM. We initially focused the analysis to on variants in genes known to cause famil-
ial malignant melanoma, but we did not identify any clearly causative variation in these genes (BAP1, CDK4, 
CDKN2A, MC1R, MITF and PTEN). Afterwards we performed an analysis of all identified variants detected by 
exome sequencing, followed by selection of variants with predicted functional impact, low population frequency 
and selection of variants adhering to the segregation pattern in the primary family. This strategy has singled out 
a rare homozygous variant in NLRP1 gene, introducing an amino-acid change of glycine at protein position 578 
to serine. The variant was present in the homozygous state in both patients with concurrent MS and MM pheno-
type. Furthermore, homozygosity mapping in the two probands revealed the presence of six contiguous blocks 
of homozygous SNPs, shared by both affected individuals (Supplementary Figure 1), which narrowed the initial 
search to variants within these regions. Analysis and filtering for rare sequence variants with predicted functional 
effect in the identified blocks of homozygosity has singled out a homozygous sequence variant in the NLRP1 gene 
within chromosome 17 block of homozygosity. Analysis of coverage depth in the region of the identified variant 
did not reveal presence of gene deletions that would mimic the homozygous status of the identified regions.
NLRP1 gene codes for the key protein component of the inflammasome complex, associated to 
vitiligo-associated multiple autoimmune disease (OMIM:193200), and other predominantly immune andma-
lignant disorders7, 8.
Further assessment of the identified variant has shown that it is located in the key functional effector domain 
of the NLRP1-encoded protein – NACHT triphosphatase domain, which mediates downstream caspase activa-
tion. Considerable evolutionary conservation of the affected amino acid was also observed (Fig. 2) and functional 
prediction algorithms (SIFT, Polyphen-2) classified the variant as pathogenic.
Genotyping of the identified variant in a 960 population control samples showed absence of the variant in a 
background population. The variant was also absent in UK10K and GoNL control populations. Carrier frequency 
in 60,657 individuals from heterogeneous populations included in the ExAC project has shown that the frequency 
of the variant in populations of European descent was exceedingly low (1.5∙10−5) and the variant was absent in 
European Finnish, East Asian and Latino populations. The variant was also observed in African populations at 
low frequency of 4.0∙10−3. No homozygous individuals have been reported in any of the population screening 
projects surveyed.
Sequencing of NLRP1 gene in an expanded cohort of familial and sporadic MS cases. We 
expanded the search for further NLRP1 associated examples of MS presenting as either familial or sporadic 
cases by exome sequencing and targeted analysis of NLRP1 in the sequencing data. We performed these analyses 
in whole exome sequencing data from probands of 38 multiplex MS families, in 44 sporadic MS cases and 92 
population-matched controls.
In familial cases of MS we identified five potentially damaging variants that were absent in the set of control 
individuals from the background population. One notable case was a frameshift Asn864ThrfsX4 variant identi-
fied in a familial MS case and absent from all control populations investigated (Table 1). The variant is predicted 
to result in the introduction of premature stop codon 4 aminoacid positions downstream of the variant site, likely 
representing a loss of function variation. The course of MS in five patients carrying these rare NLRP1 variants was 
Figure 2. Genomic context and evolutionary conservation of NLRP1 homozygous variant identified in primary 
NLRP1 family 1 (Fig. 2). Variant affects amino acid position 578 in NLRP1 gene evolutionarily invariant in all 
mammal datasets in the UCSC Genome Browser conservation chain.
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variable and included relapsing-remitting, primary progressive and benign courses. Interestingly, the case with 
the frameshift NLRP1 variant had an early reported onset of the disease with symptoms presenting at 21 years of 
age with the disease following a relapsing-remitting pattern.
In 3 individuals with familial MS (7.9%), 7 individuals with sporadic MS (15.9%) and 9 controls (9.8%), 
we also identified a set of co-occurring variants: Thr246Ser, Thr878Met, Thr995Ile, Met1119Val in Val1241Leu 
which corresponded to the autoimmunity-associated haplotype (H3) containing a set of rare missense variants in 
NLRP1, previously identified and associated with autoimmune diseases (Table 1 and Supplementary Figure 2)8. 
Although the frequency in the sporadic MS population was increased in comparison to the control population 
this difference failed to reach statistical significance (Chi-square test P = 0.21).
We also performed a statistical test of mutational burden in NLRP1 gene, including variants with moderate 
or high functional impact and below 5% in ExAC project in the analysis. We could not demonstrate an overall 
excess of potentially altering variants in the NLRP1 gene in familial MS cases (P = 0.92) when comparing them 
to control subjects. There was an excess of missense variants in the sporadic MS groups in comparison to control 
cases (P < 0.0001), likely due to a high overall number of missense variants belonging to the H3 haplotype.
Expression profiling of stimulated PBMCs. To characterize the functional impact of the variants in 
NLRP1 gene and their possible effect on the immune response in patients with MS we performed transcriptional 
and immunologic analyses. We included the patient from the primary family concomittantly affected with MS 
and MM, and also two patients from a family carrying the frameshift NLRP1 variant and in two cases from a 
family with Arg147Cys variant.
Using transcriptome sequencing of stimulated PMBCs we were able to demonstrate an overall upregulation of 
inflammasome related genes in the NOD-like receptor KEGG pathway in patients carrying putatively causative 
variants in NLRP1 (with q-value of 0.0030, Fig. 3A,B).
Expression profiling of genes after stimulation of NLRP1 pathway has shown significant differences in expres-
sion of downstream effector genes. Specifically, we detected an increased response of IL1B gene expression 
(p = 0.00046, Fig. 3C) when comparing MS mutation carriers to healthy controls.
We also surveyed the expression of effector pathways downstream of NLRP1 stimulation and detected an 
increased expression of genes belonging to several effector pathways including NFKB1, JUN AND p38 pathway 
(Supplementary Figure 3).
Discussion
In the present study we report a novel familial association of MS and MM, and propose a possible underly-
ing genetic basis in NLRP1 gene. Furthermore, we provide initial evidence of the broader implications of 
NLRP1-related pathway dysfunction in familial and sporadic MS.
In the family with familial association of MS and MM, exome sequencing in combination with homozygo-
sity mapping led us to identification of a rare homozygous sequence variant (Gly587Ser) in the NLRP1 gene 
predicted to affect function, suggesting an autosomal recessive genetic predisposition. The variant encompasses 
a change of a highly evolutionary conserved amino acid residue of the NACHT domain which is required for 
proper NLRP1 inflammasome oligomerization and assembly9. Notably, pathologic variants in NACHT domain 
of NLRP3 inflammasome counterpart have already been shown to cause inherited NLRP3-related autoinflamma-
tory syndromes10, 11. The role of NLRP1 in the pathogenesis of MM is supported by reported genetic association7 
and constitutive activation of NLRP1 inflammasome leading to persistently increased production of downstream 
mediators (Caspase-1 and IL-1β) in malignant melanoma tissue12. Multiple sclerosis and malignant melanoma 
have previously only been associated in epidemiological studies as comorbid conditions4, yet evidence of famil-
ial co-ocurrence and shared etiological origin of these two diseases has not been reported to date. Whilst there 
have been reports linking specific immunomodulating drugs currently used in treatment of MS and increased 










17 5445285 T — Frameshift c.2591delA Asn864fsX4 0,000% 0,000% / /
17 5424908 C T Missense c.3719G > A Arg1240His 0,003% 0,000% B T
17 5485999 G A Missense c.439C > T Arg147Cys 0,010% 0.004% B T
17 5461960 T C Missense c.2056A > G Met686Val 0,039% 0,000% P D
17 5463093 C T Missense c.923G > A Arg308Gln 0,110% 0,009% B T
17 5445243 G A Missense c.2633C > T Thr878Met 4,429% 7,500% B T
17 5463279 G C Missense c.737C > G Thr246Ser 4,409% 7,200% B T
17 5437285 G A Missense c.2984C > T Thr995Ile 4,772% 7,200% P T
17 5433966 T C Missense c.3355A > G Met1119Val 4,808% 7,600% B T
17 5424906 C G Missense c.3721G > C Val1241Leu 4,875% 7,500% B T
Table 1. Rare, possibly pathogenic variants in the NLRP1 gene are presented, along with their functional 
impact, frequency in ExAC populations of European descent and theoretical predictions of pathogenicity. All 
the listed variants were identified in cases with familial MS, with the frequency in control populations below 5%. 
*Minor allele frequency (MAF) in the population-matched background population of 1000 population matched 
exomes.
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susceptibility to MS, both affected sibs of the primary family affected by MS and MM were not treated with these 
or similar therapies.
Furthermore, we found several additional possibly associated sequence variants in the NLRP1 gene, one novel 
frameshift variant (Asn864ThrfsTer4) and 4 rare missense NLRP1 variants in distinct MS families. We also iden-
tified the presence of H3 haplotype associated with immune disease susceptibility in MS patients and controls, but 
statistical comparisons failed to reveal difference in frequency between the groups of familial MS, sporadic MS 
and control subjects. Interestingly, when the sum of all moderate to high impact variants with frequency below 
5% was taken into consideration with burden analysis we could observe a significant excess of moderate to high 
impact variants in patients with sporadic MS.
Functional immunologic studies in selected patients with putatively pathogenic NLRP1 variants have shown 
that stimulation of PBMCs in variant carriers resulted in overexpression of downstream effector IL-1β in patients 
with NLRP1. Whole transcriptome profiling of PBMCs further showed overexpression of complete NOD-like 
receptor pathway and components of downstream NFKB, JNK and p38 pathways which were previously impli-
cated in the MS pathology13–15.
The role of the IL-1β has been implicated in a variety of inflammatory and neurodegenerative processes 
occurring in multiple sclerosis. There is evidence that IL-1β induces trans-endothelial migration of activated 
leukocytes across the blood-brain barrier of the central nervous system16, exacerbates central neuroinflammation 
Figure 3. Immunological and transcriptional characterization of PBMCs response to NLRP1 pathway 
stimulation in MS patients carrying putatively pathogenic variants in NLRP1 gene in comparison to healthy 
controls. (A) depicts results of RNAseq transcriptional profiling for a selection of genes belonging to broad 
inflammasome pathway as defined by KEGG NOD-like receptor pathway. A tendency towards upregulation of 
genes in the pathway is present and the recapitulated with GSEA pathway analysis, presented in (B) showing 
a tendency of the pathway towards upregulation. (C) depicts characterization of IL-1β as the main effector of 
NLRP1 pathway activation. We were able to both validate the increased expression of IL1B detected in RNAseq 
and to demonstrate increased production of IL-1β. The specificity of findings for IL-1β was demonstrated by 
measuring TNF-α production in the same cell culture supernatants (data not shown)8. There was no significant 
difference in the TNF-α secretion between PBMCs of MS patients with mutations in NLRP1 gene and healthy 
subjects. The * and ** annotations in (C) denote significance attained at threshold P = 0.05 and P = 0.01, 
respectively. The intervals correspond to standard error measure (SEM) of the measurements.
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independently of the blood-brain barrier integrity15 and facilitates T helper 17 cell induction17. IL-1β is present in 
the CNS lesions in MS18 and its concentration is increased in CSF fluid of patients with MS19 and correlates with 
cortical pathology load20.
Animal studies lend further support to the role of NLRP1 in susceptibility to multiple sclerosis. In a recent 
study by Masters et al., mice carrying a semi-dominant pathogenic variant (Q593P) in Nlrp1a ortholog of NLRP1 
were shown to display a distinct phenotype of multisystemic inflammatory disease that also prominently affected 
the central nervous system21. While the mouse models with Nlrp1a functional variants usually presented with 
notably altered immunological profiles, our patients’ immunological profiles were within physiological range in 
the resting state. It is thus possible that the identified variants exert abnormal stimuli upon external provocation 
by either infectious or other environmental provocations.
Inflammasomes constitute molecular sensor systems activated by environmental stimuli such as cellular infec-
tion (viral, bacterial and prokaryotic) or other stressors, and as such present an interface to a variety of exposures 
triggering the cellular inflammatory response22. There is an increasing body of evidence corroborating the role 
of viral infection, UV light exposure, smoking and other stimuli, known to increase the susceptibility to MS23, 24.
Based on our results we hypothesize that the combination of genetic predisposition for increased stimulation 
of NLRP1 pathway to various environmental exposures may contribute to compromised blood-brain barrier 
integrity, recurrent active demyelination and neurodegeneration observed in MS.
Evidence for the role of inflammasome in the pathogenesis expands the field of potential therapeutic inter-
vention in MS. Biological treatments targeting IL-1 signaling have been approved for treatment of various 
auto-inflammatory and autoimmune disorders25. Specifically, human monoclonal antibodies against IL-1β 
(canakinumab) have shown clinical benefit in patients with NLRP3-related disorders, while clinical trials for use 
in autoimmune disorders are already underway25.
In conclusion, we present a novel familial association of MS and MM and identify a possible genetic basis for 
this association in the NLRP1 gene. We identified additional candidate variants in NLRP1 gene in an expanded 
cohort of patients with familial MS. The role of human inflammasome at the interface between genetic predis-
position and environment may offer further insight in the pathogenesis, prevention and treatment of multiple 
sclerosis.
Methods
Ethical statement. The study was performed in accordance with the principles stated in the Declaration of 
Helsinki. The study on hereditary risk factors in multiple sclerosis was approved by the National Medical Ethics 
Committee (90/08/12). All participants gave informed written consent to participate in the study.
Genetic and functional analyses. We performed whole exome sequencing in affected probands of the 
primary family (Family 1, with concurrent multiple sclerosis and malignant melanoma), followed by homozy-
gosity mapping and characterization of discovered candidate variants, which singled out putatively pathogenic 
variation in NLRP1 gene. We further expanded the search for pathogenic NLRP1 variants in an expanded set of 
38 patients with familial MS and 58 patients with sporadic MS and identified two further MS families carrying 
potentially pathologic NLRP1 variants. To functionally characterize NLRP1 genetic variants we performed tar-
geted immunologic stimulation of NLRP1 pathway in patients with putatively pathogenic NLRP1 variants and 
healthy controls. In stimulated PBMCs we measured the activity of downstream NLRP1 effectors and performed 
whole transcriptome profiling using RNAseq followed by targeted quantitative PCR validation of identified gene 
expression alterations.
Exome sequencing. Aiming to survey the presence of potential causative genetic variation in the MSMM 
family we performed exome sequencing of both affected probands in the primary family (Fig. 1). The sequencing 
was performed after whole human exome target capture with Agilent SureSelect v4 capture kit. Sequencing of 
enriched shotgun library was performed on HiSeq 2000 platform in the paired-end mode. We reached median 
on target coverage exceeding 50x in both affected sibs (denoted MSMM001 and MSMM002), assuring sufficient 
variant detection rate in both cases. The detailed variant filtration and exome data analysis strategies are presented 
in Supplementary Methods.
We also performed homozygosity mapping in exome data, utilizing the HomozygosityMapper tool (available 
at www.homozygositymapper.org 26). Only the variants in regions covered at 50x depth or more were included in 
this analysis and minimal block sizes was set at 20 variants, while leaving other parameters in their default state.
Population screening of identified variants in general population. Screening for sequence variants 
identified in MS patients was performed in 960 population control samples using custom designed KASPAR gen-
otyping assays (LGC) using ABI 3000 Sequence Detection System (Applied Biosystems) as previously described 
and in accordance with manufacturers recommendations27.
Exome sequencing in an expanded group of MS patients. We have selected further 96 samples with 
MS for targeted interrogation of coding sequence variants in NLRP1 genes with Sanger sequencing. Of these, 38 
samples originated from index cases in multiplex families with at least two affected members while the remaining 
58 cases were sporadic. As with sequencing in the primary MSMM family, exome sequencing was performed 
using Illumina Nextera Coding Exome pull-out protocol followed by sequencing on Illumina HiSeq 2500 and 
bioinformatics analysis using in-house pipelines, as described above.
Isolation and stimulation of PBMCs. Detailed methods for isolation and stimulation of PBMCs are pre-
sented in the Supplementary Materials.
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Immune status of subjects. Detailed methods for determination of immune status of the patients are 
presented in the Supplementary Materials.
RNAseq and quantitative PCR experiments. Detailed methods for RNAseq and qPCR experiments are 
presented in the Supplementary Materials.
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